Glenmark’s US arm settles generic drug pricing case for $29.6 million
Glenmark Pharmaceuticals said its US subsidiary has agreed to pay $29.628 million (approximately ₹284 crore) to settle antitrust and consumer protection litigation linked to allegations of generic drug price-fixing in the United States. The settlement involves Glenmark Pharmaceuticals Inc., USA and a group of state attorneys general in the US. The amount will be paid…
